A massive French study suggests that the type of progesterone used in postmenopausal HRT is the decisive factor in determining the breast cancer risk associated with hormone therapy. Synthetic progestins appear to increase risk, while bio-identical progesterone does not. Digital mammography can improve detection of breast cancers in younger women with dense breasts, but the cost is high.